One such company that might be well-positioned for future earnings growth is Gilead Sciences Inc. (GILD). This firm, which is in the Med-Biomed/Generic, saw EPS growth of 11.0% last year, and is looking great for this year too.
In fact, the current growth estimate for this year calls for earnings-per-share growth of significant amount. Furthermore, the long-term growth rate is currently an impressive 29.9%, suggesting pretty good prospects for the long haul.
And if this wasn’t enough, the stock has actually seen estimates rise over the past month for the current fiscal year by about 21.4%. Thanks to this rise in earnings estimates, GILD has a Zacks Rank #1 (Strong Buy) which further underscores the potential for outperformance in this company.
So if you are looking for a fast growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider GILD. Not only does it have double digit earnings growth prospect, but its impressive Zacks Rank suggests that analysts believe better days are ahead for GILD as well.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
GILEAD SCIENCES INC (GILD): Free Stock Analysis Report
Zacks Investment Research